1. Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase
- Author
-
Ueli Gubler, Nina M. Goodey, John J. Siekierka, Romy Perez-Abraham, Karla Garabiles Sanchez, and Melany Alfonso
- Subjects
0301 basic medicine ,Cycloguanil ,Gene Expression ,Catalysis ,Brugia malayi ,03 medical and health sciences ,chemistry.chemical_compound ,parasitic diseases ,Dihydrofolate reductase ,medicine ,Animals ,Enzyme kinetics ,chemistry.chemical_classification ,biology ,Chemistry ,030111 toxicology ,Helminth Proteins ,biology.organism_classification ,Molecular biology ,Recombinant Proteins ,Dissociation constant ,Tetrahydrofolate Dehydrogenase ,030104 developmental biology ,Pyrimethamine ,Enzyme ,Biochemistry ,Antifolate ,biology.protein ,Biotechnology ,medicine.drug - Abstract
Brugia malayi (B. malayi) is one of the three causative agents of lymphatic filariasis, a neglected parasitic disease. Current literature suggests that dihydrofolate reductase is a potential drug target for the elimination of B. malayi. Here we report the recombinant expression and purification of a ∼20 kDa B. malayi dihydrofolate reductase (BmDHFR). A His6-tagged construct was expressed in E. coli and purified by affinity chromatography to yield active and homogeneous enzyme for steady-state kinetic characterization and inhibition studies. The catalytic activity kcat was found to be 1.4 ± 0.1 s(-1), the Michaelis Menten constant KM for dihydrofolate 14.7 ± 3.6 μM, and the equilibrium dissociation constant KD for NADPH 25 ± 24 nM. For BmDHFR, IC50 values for a six DHFR inhibitors were determined to be 3.1 ± 0.2 nM for methotrexate, 32 ± 22 μM for trimethoprim, 109 ± 34 μM for pyrimethamine, 154 ± 46 μM for 2,4-diaminoquinazoline, 771 ± 44 μM for cycloguanil, and >20,000 μM for 2,4-diaminopyrimidine. Our findings suggest that antifolate compounds can serve as inhibitors of BmDHFR.
- Published
- 2016